DUBLIN–(BUSINESS WIRE)–The “Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult) – Global forecast to 2030” has been added to ResearchAndMarkets.com’s offering.
The global compounding pharmacy market is on track to expand significantly, projected to achieve USD 19.41 billion by 2030, up from an estimated USD 14.72 billion in 2025, reflecting a CAGR of 5.7% from 2025 to 2030. Market expansion is primarily driven by the shift towards personalized dosing, although challenges in API and excipient supply and CCI/testing may act as constraints.
The oral drugs segment is prominent in the compounding pharmacy market. Within the market, product segmentation includes oral, topical, parenteral, rectal, nasal, ophthalmic drugs, and more. The oral drugs segment stands out due to the growing emphasis on customized therapies meeting individual patient needs. It encompasses a range of formulations such as capsules, tablets, lozenges, and solutions critical for treatments like hormone replacement, pediatric and geriatric care, pain management, and chronic disease interventions.
Compounded oral medications allow pharmacists to adjust dosages, flavors, excipients, and release profiles, enhancing patient compliance, especially for those unable to swallow standard tablets or requiring specific dosages. The increased incidence of chronic illnesses like cardiovascular and endocrine disorders further underscores demand for personalized oral therapies, aiming to optimize efficacy and minimize side effects. Advances in sustained-release systems and bioavailability enhancement are bolstering therapeutic outcomes. Compliance with FDA and USP standards ensures the integrity of these compounded solutions, strengthening trust with both physicians and patients. As a result, personalized medication, supported through hospitals and retail outlets, remains a growth engine for the oral drugs segment.
The pain management segment dominates therapeutic applications as of 2024. This segment sees substantial shareholding due to prevalent acute and chronic pain issues affecting musculoskeletal, neuropathic, and post-surgical patient demographics. Conditions like arthritis and migraines have escalated the need for effective pain medications, including NSAIDs, opioids, and innovative combinations. The advent of personalized options such as sustained-release formulations enhances efficacy, minimizes side effects, and boosts patient adherence.
Technological advancements, like transdermal patches, have broadened options and simplified long-term management. Growing insurance support, increased recognition of pain as a serious health concern, and an aging population contribute to steady segment growth. Pharmaceutical leaders are continually expanding their portfolios with novel analgesics and alternatives to opioids, aiming to capture significant market shares. This therapeutic segment is poised to retain its dominance, adaptive to both established and emerging market trends.
North America leads the global compounding pharmacy market from 2025 to 2030. Dominance in this region, particularly by the US, is attributed to a robust healthcare framework, tight regulatory oversight, and the presence of numerous compounding pharmacies. The market supports diverse compounded products, particularly crucial when commercial alternatives are inadequate.
Demand is surging for specialized compounded medications in sectors like pain management and pediatric care, bolstered by the FDA’s regulatory dedication to ensuring safety and quality, enhancing trust. These dynamics position North America as pivotal in advancing compounding pharmacy services across the globe.
Research Insights and Market Highlights:
- Primary interviews indicate a split of 70% supply-side and 30% demand-side respondents. By designation, 45% were managers, 30% CXO and directors, and 25% executives, across regions of North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%).
- Key players cited include Baxter, Empower Pharmacy, B. Braun, Fagron, QuVa Pharma, and others. Strategic insights into industry dynamics are included, covering product launches, collaborations, and market influence factors.
This comprehensive report provides estimations, competitive landscape analysis, and strategic insights for stakeholders to effectively navigate and capitalize on the compounding pharmacy market, focusing on growth drivers, restraints, and strategic opportunities.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 305 |
| Forecast Period | 2025-2030 |
| Estimated Market Value (USD) in 2025 | $14.72 Billion |
| Forecasted Market Value (USD) by 2030 | $19.41 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
Market Dynamics
- Drivers
- Persistent Drug Shortages in North America and Europe
- Enforcement of USP Standards
- Push for Ready-To-Administer (RTA) and Standardized Doses
- Continued Demand-Supply Gap for GLP-1 Drugs
- Trend Towards Personalization of Doses
- Restraints
- Resolution of GLP-1 Shortages and Reduced Reliance on Compounded Alternatives
- Stricter FDA Oversight and Intensified Enforcement of Unsanitary Conditions Violations
- Limitations on Bulk Drug Substances
- Opportunities
- Expansion of Hospital Outsourcing into Anesthesia, Critical Care, Ophthalmic, and Chemo-Adjuncts
- Radiopharmaceutical Compounding Standardization
- Challenges
- Capacity Bottlenecks in API, Excipient Supply, and Critical Compounding Infrastructure Testing
- Limited Quality-System Maturity and Gaps in Stability/BUD Evidence Generation
Company Profiles
- Baxter
- Empower Pharmacy
- B. Braun SE
- Fagron
- Quva Pharma, Inc.
- Sca Pharma
- Nephron Pharmaceuticals
- Leiters Health
- Icon Group
- Roseway Labs
- Ith Pharma
- Pencol Compounding Pharmacy
- Formul8
- Aurora Compounding Pharmacy
- Custom Med Apothecary
- Institutional Pharmacy Solutions
- Fusion Apothecary
- Innovation Compounding Pharmacy
- Rx3 Compounding Pharmacy
- Dougherty’s Pharmacy, Inc.
- Lorraine’s Pharmacy
- Wells Pharma
- Olympia Pharmacy
- Fresh Therapeutics
- Medios AG
For more information about this report visit https://www.researchandmarkets.com/r/a5987r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
